Inflammation Modulation by Vitamin D and Calcium in the Morphologically Normal Colorectal Mucosa of Patients with Colorectal Adenoma in a Clinical Trial.
Study Goal
The researchers aimed to determine whether supplemental calcium (1,200 mg/day) affects COX-2 and 15-HPGD expression in the rectal mucosa of patients with colorectal adenoma.
Results Summary
The study found that calcium supplementation, either alone or combined with vitamin D, reduced the COX-2/15-HPGD expression ratio, suggesting a potential anti-inflammatory and anti-carcinogenic effect in colorectal tissue.
Population
62 patients with a history of colorectal adenoma.
Effective Dosage
1,200 mg/day
Duration
1 year
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
vitamin D and calcium | decrease | prostaglandin-mediated inflammation and colorectal carcinogenesis pathways | - | - | may inhibit | #1 |
supplemental vitamin D (1,000 IU/day) and/or calcium (1,200 mg/day) | neutral | COX-2 and 15-HPGD expression | 62 patients with colorectal adenoma | - | tested the effects | #2 |
supplemental vitamin D (1,000 IU/day) and/or calcium (1,200 mg/day) | decrease | COX-2/15-HPGD expression ratio | 62 patients with colorectal adenoma | 47% | decreased | #3 |
Increased COX-2 and decreased 15-hydroxyprostaglandin dehydrogenase (15-HPGD) expression promote prostaglandin-mediated inflammation and colorectal carcinogenesis. Experimental studies suggest that vitamin D and calcium may inhibit these pathways, but their effects on colorectal tissue COX-2 and 15-HPGD expression in humans are unknown. We tested the effects of supplemental vitamin D (1,000 IU/day) and/or calcium (1,200 mg/day) on COX-2 and 15-HPGD expression in the morphologically normal rectal mucosa from 62 paients with colorectal adenoma in a placebo-controlled chemoprevention trial. We measured biomarker expression using automated IHC and quantitative image analysis at baseline and 1-year follow-up, and assessed treatment effects using mixed linear models. The primary outcome was the COX-2/15-HPGD expression ratio, because these enzymes function as physiologic antagonists. After 1 year of treatment, the mean COX-2/15-HPGD expression ratio in full-length crypts proportionately decreased 47% in the vitamin D group (